Services
Executive Summary
The use of PET (Positron Emission Tomography) imaging for oncology, cardiology and neurology applications is growing explosively. From 1999 to 2001 the number of sites in the U.S. using PET imaging increased by 200% from 240 to 690. During the same period, the installed base of PET scanners grew by 200% from 70 to 220. * This growth was mirrored by an increase in the number of accelerator facilities producing F-18 FDG and other PET imaging agents.
In response to this market opportunity, Cyclomedical Applications Group, LLC was formed in 2002 to serve owners and operators of medical accelerators dedicated to the production of positron emitting radioisotopes such as F-18. Cyclomedical Applications Group is an organization of experienced radiopharmaceutical executives that provide consultation and assistance in the areas of accelerator facility planning, equipment procurement and installation, regulatory submission, medical accelerator consulting assistance and accelerator facility management. These services can range from short-term consultation to longer term retainer arrangements. Cyclomedical Applications Group can address a specific problem faced by an accelerator facility, or it can adopt a monitoring posture in support of an in-place management team, or it can provide comprehensive management of the operation. The benefit for the accelerator owner/operator is the convenience and economy of a full range of services through one contractor on an “as needed” basis.
By remaining independent from equipment suppliers and commercial distributors of PET imaging products, Cyclomedical Applications Group offers a unique service to the entire PET market. The group has the ability and experience to work with all of the major accelerator producers–GE, CTI, AccSys, IBA and EBCO.
The management of Cyclomedical Applications Group illustrates the breadth of experience and skills that are offered to clients. Dr. James Lamb, President is a pioneer in the development of the production process for F-18 FDG. During his career he has held senior positions with major companies in the PET industry and has founded and operated two radiopharmaceutical companies. He has served as general manager of FDG production and distribution operations at accelerators in Denver, Jacksonville and Baltimore. Mr. Will Lepeska, Vice-President of Business Development, was an early player in the nuclear medicine business, and founder and owner of Hospital Financial Corporation, a pioneer in the leasing of medical imaging equipment. Mr. David Drummond, Vice-President of International Marketing, has more than twenty-five years of experience in the nuclear medicine field in both North America and Europe, and is the founder of isoSolutions Inc. in Canada, which provides business services to the nuclear medicine industry. The capabilities of Cyclomedical Applications Group are further broadened by a similarly experienced team of Associates.
* IMV Medical Information Division, “First Edition of IMV’s PET Census Profiles Early Adopters of PET Technology”, News Release, 2002 September 16
Next: Concept